Xeris Biopharma Holdings (XERS) Inventory (2020 - 2026)

Xeris Biopharma Holdings' Inventory history runs 7 years deep, the most recent figure standing at $74.2 million for Q1 2026.

• Quarterly Inventory rose 40.89% year-over-year to $74.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $74.2 million (up 40.89% YoY) and the FY2025 annual result came in at $68.7 million, up 42.55% from the prior year.
• Inventory was $74.2 million for Q1 2026 at Xeris Biopharma Holdings, up from $68.7 million in the prior quarter.
• Across five years, Inventory topped out at $74.2 million in Q1 2026 and bottomed at $16.9 million in Q1 2022.
• A 5-year average of $42.9 million and a median of $40.9 million in 2024 frame the typical range for Inventory.
• Annual changes were most pronounced in 2023 — Inventory soared 104.27% — and 2024, when it advanced 17.62%.
• Xeris Biopharma Holdings' Inventory stood at $24.7 million in 2022, then surged by 57.02% to $38.8 million in 2023, then advanced by 24.04% to $48.2 million in 2024, then surged by 42.55% to $68.7 million in 2025, then advanced by 8.1% to $74.2 million in 2026.
• Business Quant data shows XERS's Inventory at $74.2 million in Q1 2026, $68.7 million in Q4 2025, and $67.5 million in Q3 2025.